Mgrm
- Creatore Discussione coffeman
- Data di inizio
-
ANNUNCIO: Segui le NewsLetter di Borse.it.
Al via la Newsletter di Borse, con tutte le notizie quotidiane sui mercati finanziari. Iscriviti per rimanere aggiornato con le ultime News di settore, quotazioni e titoli del momento.
Per iscriverti visita questo link.
coffeman
Nuovo Utente
- Registrato
- 14/6/04
- Messaggi
- 29.838
- Punti reazioni
- 1.173
gasfin ha scritto:sono bruciato ho metà del fol addosso !
che bruciato Gas tu sei il presidente e poi un trader soft che trader è ,il trader è un giocatore con una forte carica di adrenalina come te e come me.
saluti coffeman
dagoweb
Brigata Falkland
- Registrato
- 20/1/04
- Messaggi
- 5.526
- Punti reazioni
- 266
Visto che c'e' gia' un 3d ...
Le ultime candele indicano una certa indecisione, ma tant'e' ...
... faccio affidamento sull'investimento di 25 milioni di Pfizer e sul parterre di istituzionali che sono dentro ( http://finance.yahoo.com/q/mh?s=MGRM )
Cosa fa :
(Hiv products)
Monogram Biosciences HIV Assays — Providing information to help patients get the most from antiretroviral therapy
The treatment of HIV is complicated. It is difficult for infected individuals who must live with complex regimens, side effects, drug resistance, and other issues, and it is a challenge for healthcare providers who work hard to make sure that their patients are getting the right drugs, finding ways to cope with side effects, and most importantly, staying healthy. Monogram has developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. Our phenotype and genotype resistance tests, phenotype + genotype combination test, and viral fitness test are intended to help healthcare providers choose the drugs that will provide the greatest benefit to the individual and to help get the most out of antiretroviral therapy over the long term.
PhenoSense GT
PhenoSense GT™ gives you the complete picture of resistance. It's the only assay combining actual phenotype and genotype drug resistance results in a single report. PhenoSense GT™ also includes a measure of replication capacity (RC), sometimes called viral fitness, and HIV-1 subtype.
Choosing PhenoSense GT™ after 2 regimen failures allows you to retain options in your drug-regimen strategy that may preserve drug choices for a later time. While sophisticated in its technology, PhenoSense GT™ remains user-friendly. Our report form now includes updated upper and lower clinical cutoffs and a new summary page.
Even in complex cases, PhenoSense GT™ brings clarity to your treatment choices. Both phenotypic and genotypic results come from the same blood sample, so it's possible to resolve disagreement between them. This comprehensive assay gives you advanced, practical insight into viral susceptibility.
PhenoSense HIV
PhenoSense™ HIV is a phenotypic HIV drug resistance test and is the most widely used phenotypic test today. PhenoSense HIV is successful based on the quality of the test — utilizing proprietary leading-edge technology for a direct, rapid, and precise measure of a patient's virus' sensitivity to antiretroviral drugs. Test results allow healthcare professionals to review the level of susceptibility or resistance that a person has to each antiretroviral drug in order to design an individualized treatment plan. PhenoSense HIV drug resistance results are also provided with a measure of viral fitness, or Replication Capacity (RC).
The report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
GeneSeq HIV
GeneSeq™ HIV is a highly accurate genotypic HIV drug resistance test. The test is performed using state-of-the-art technology and the results are determined using the most recently updated HIV mutation information and information from scientific research and Monogram's resistance experts.
The report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
PhenoSense Entry
PhenoSense Entry™ is the only commercially available phenotypic test for measuring susceptibility to entry inhibitors.
Together with PhenoSense GT™ (our combination phenotype/genotype drug resistance test), PhenoSense Entry™ provides the most complete picture of resistance to antiretroviral medications.
PhenoSense Entry™ assesses resistance to Fuzeon® (enfuvirtide), which interacts with glycoprotein gp41 of the HIV envelope. The assay also assesses resistance to entry inhibitors that interact with gp120 (eg, chemokine receptor antagonists, attachment inhibitors), and is used in their clinical development. It is the gold standard for assessing resistance to current and future entry inhibitors.
Alternative approaches may not account for the high genetic heterogeneity observed in this part of the virus.
Replication Capacity (RC)
The Replication Capacity (RC) assay measures HIV's ability to make copies of itself, or replicate. RC testing is a way to measure the fitness of HIV. The test is performed by comparing an individual's virus to a reference, or wild-type, virus that is known to be good at making copies of itself. The wild-type virus has an RC of 100%. Knowing the RC of a patient's virus can help healthcare providers decide whether to delay, start, stop, switch, or interrupt treatment for the patient.
The RC assay is available with both the PhenoSense GT and PhenoSense HIV drug resistance assays. The RC results appear on the PhenoSense GT and PhenoSense HIV reports.
(Oncology products)
More than one million new cases of solid tumor cancer are diagnosed each year in the US, with four cancer types (breast, prostate, lung and colorectal) accounting for over 700,000 of these. Despite varied therapeutic modalities — surgery, radiation, chemotherapy, and biotherapeutics — healthcare providers have a critical unmet need for more accurate prognostic and diagnostic tools and more effective, safer therapeutics.
Monogram Biosciences' unique eTag™ technology can accelerate the development of targeted therapeutics, improve clinical trial design and results, clarify and individualize the selection of medications, and optimize outcomes for patients with cancer and other serious diseases.
A more comprehensive understanding of the biology involved in cancer cell growth and drug response, especially at the level of proteins, protein complexes and signaling pathways (which constitute the target for most drugs), is required to enable healthcare providers to select the right therapy. Effective predictive tests can identify the presence of the proteins and protein complexes upon which the drugs in question act, providing valuable information on the likelihood of a response in a particular patient. Our eTag technology has the capability to measure these proteins and signaling pathways in their activated state.
Le ultime candele indicano una certa indecisione, ma tant'e' ...
... faccio affidamento sull'investimento di 25 milioni di Pfizer e sul parterre di istituzionali che sono dentro ( http://finance.yahoo.com/q/mh?s=MGRM )
Cosa fa :
(Hiv products)
Monogram Biosciences HIV Assays — Providing information to help patients get the most from antiretroviral therapy
The treatment of HIV is complicated. It is difficult for infected individuals who must live with complex regimens, side effects, drug resistance, and other issues, and it is a challenge for healthcare providers who work hard to make sure that their patients are getting the right drugs, finding ways to cope with side effects, and most importantly, staying healthy. Monogram has developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. Our phenotype and genotype resistance tests, phenotype + genotype combination test, and viral fitness test are intended to help healthcare providers choose the drugs that will provide the greatest benefit to the individual and to help get the most out of antiretroviral therapy over the long term.
PhenoSense GT
PhenoSense GT™ gives you the complete picture of resistance. It's the only assay combining actual phenotype and genotype drug resistance results in a single report. PhenoSense GT™ also includes a measure of replication capacity (RC), sometimes called viral fitness, and HIV-1 subtype.
Choosing PhenoSense GT™ after 2 regimen failures allows you to retain options in your drug-regimen strategy that may preserve drug choices for a later time. While sophisticated in its technology, PhenoSense GT™ remains user-friendly. Our report form now includes updated upper and lower clinical cutoffs and a new summary page.
Even in complex cases, PhenoSense GT™ brings clarity to your treatment choices. Both phenotypic and genotypic results come from the same blood sample, so it's possible to resolve disagreement between them. This comprehensive assay gives you advanced, practical insight into viral susceptibility.
PhenoSense HIV
PhenoSense™ HIV is a phenotypic HIV drug resistance test and is the most widely used phenotypic test today. PhenoSense HIV is successful based on the quality of the test — utilizing proprietary leading-edge technology for a direct, rapid, and precise measure of a patient's virus' sensitivity to antiretroviral drugs. Test results allow healthcare professionals to review the level of susceptibility or resistance that a person has to each antiretroviral drug in order to design an individualized treatment plan. PhenoSense HIV drug resistance results are also provided with a measure of viral fitness, or Replication Capacity (RC).
The report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
GeneSeq HIV
GeneSeq™ HIV is a highly accurate genotypic HIV drug resistance test. The test is performed using state-of-the-art technology and the results are determined using the most recently updated HIV mutation information and information from scientific research and Monogram's resistance experts.
The report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
PhenoSense Entry
PhenoSense Entry™ is the only commercially available phenotypic test for measuring susceptibility to entry inhibitors.
Together with PhenoSense GT™ (our combination phenotype/genotype drug resistance test), PhenoSense Entry™ provides the most complete picture of resistance to antiretroviral medications.
PhenoSense Entry™ assesses resistance to Fuzeon® (enfuvirtide), which interacts with glycoprotein gp41 of the HIV envelope. The assay also assesses resistance to entry inhibitors that interact with gp120 (eg, chemokine receptor antagonists, attachment inhibitors), and is used in their clinical development. It is the gold standard for assessing resistance to current and future entry inhibitors.
Alternative approaches may not account for the high genetic heterogeneity observed in this part of the virus.
Replication Capacity (RC)
The Replication Capacity (RC) assay measures HIV's ability to make copies of itself, or replicate. RC testing is a way to measure the fitness of HIV. The test is performed by comparing an individual's virus to a reference, or wild-type, virus that is known to be good at making copies of itself. The wild-type virus has an RC of 100%. Knowing the RC of a patient's virus can help healthcare providers decide whether to delay, start, stop, switch, or interrupt treatment for the patient.
The RC assay is available with both the PhenoSense GT and PhenoSense HIV drug resistance assays. The RC results appear on the PhenoSense GT and PhenoSense HIV reports.
(Oncology products)
More than one million new cases of solid tumor cancer are diagnosed each year in the US, with four cancer types (breast, prostate, lung and colorectal) accounting for over 700,000 of these. Despite varied therapeutic modalities — surgery, radiation, chemotherapy, and biotherapeutics — healthcare providers have a critical unmet need for more accurate prognostic and diagnostic tools and more effective, safer therapeutics.
Monogram Biosciences' unique eTag™ technology can accelerate the development of targeted therapeutics, improve clinical trial design and results, clarify and individualize the selection of medications, and optimize outcomes for patients with cancer and other serious diseases.
A more comprehensive understanding of the biology involved in cancer cell growth and drug response, especially at the level of proteins, protein complexes and signaling pathways (which constitute the target for most drugs), is required to enable healthcare providers to select the right therapy. Effective predictive tests can identify the presence of the proteins and protein complexes upon which the drugs in question act, providing valuable information on the likelihood of a response in a particular patient. Our eTag technology has the capability to measure these proteins and signaling pathways in their activated state.
dagoweb
Brigata Falkland
- Registrato
- 20/1/04
- Messaggi
- 5.526
- Punti reazioni
- 266
(Dati del 2/6/2006)
Key Statistics Get Key Statistics for:
Data provided by Capital IQ, except where noted.
VALUATION MEASURES
Market Cap (intraday): 247.56M
Enterprise Value (2-Jun-06)3: 180.90M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-07) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 4.81
Price/Book (mrq): 5.72
Enterprise Value/Revenue (ttm)3: 3.51
Enterprise Value/EBITDA (ttm)3: -18.3
FINANCIAL HIGHLIGHTS
Fiscal Year
Fiscal Year Ends: 31-Dec
Most Recent Quarter (mrq): 31-Mar-06
Profitability
Profit Margin (ttm): -65.19%
Operating Margin (ttm): -28.95%
Management Effectiveness
Return on Assets (ttm): -8.12%
Return on Equity (ttm): -59.63%
Income Statement
Revenue (ttm): 51.51M
Revenue Per Share (ttm): 0.407
Qtrly Revenue Growth (yoy): 32.60%
Gross Profit (ttm): 28.25M
EBITDA (ttm): -9.89M
Net Income Avl to Common (ttm): -33.65M
Diluted EPS (ttm): -0.27
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 67.42M
Total Cash Per Share (mrq): 0.517
Total Debt (mrq): 756.00K
Total Debt/Equity (mrq): 0.017
Current Ratio (mrq): 1.476
Book Value Per Share (mrq): 0.332
Cash Flow Statement
Operating Cash Flow (ttm): -10.96M
Levered Free Cash Flow (ttm): 32.74M
TRADING INFORMATION
Stock Price History
Beta: 2.86
52-Week Change3: -28.84%
S&P500 52-Week Change3: 6.76%
52-Week High (13-Jun-05)3: 2.85
52-Week Low (18-Apr-06)3: 1.33
50-Day Moving Average3: 1.81
200-Day Moving Average3: 1.84
Share Statistics
Average Volume (3 month)3: 1,073,060
Average Volume (10 day)3: 1,783,640
Shares Outstanding: 130.30M
Float: 129.22M
% Held by Insiders4: 12.87%
% Held by Institutions4: 67.10%
Shares Short (as of 10-May-06)3: 7.94M
Short Ratio (as of 10-May-06)3: 4.9
Short % of Float (as of 10-May-06)3: 6.10%
Shares Short (prior month)3: 6.79M
Dividends & Splits
Forward Annual Dividend Rate5: N/A
Forward Annual Dividend Yield5: N/A
Trailing Annual Dividend Rate3: N/A
Trailing Annual Dividend Yield3: NaN%
5 Year Average Dividend Yield5: N/A
Payout Ratio5: N/A
Dividend Date3: N/A
Ex-Dividend Date5: N/A
Last Split Factor (new per old)2: N/A
Last Split Date3: N/A
Key Statistics Get Key Statistics for:
Data provided by Capital IQ, except where noted.
VALUATION MEASURES
Market Cap (intraday): 247.56M
Enterprise Value (2-Jun-06)3: 180.90M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-07) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 4.81
Price/Book (mrq): 5.72
Enterprise Value/Revenue (ttm)3: 3.51
Enterprise Value/EBITDA (ttm)3: -18.3
FINANCIAL HIGHLIGHTS
Fiscal Year
Fiscal Year Ends: 31-Dec
Most Recent Quarter (mrq): 31-Mar-06
Profitability
Profit Margin (ttm): -65.19%
Operating Margin (ttm): -28.95%
Management Effectiveness
Return on Assets (ttm): -8.12%
Return on Equity (ttm): -59.63%
Income Statement
Revenue (ttm): 51.51M
Revenue Per Share (ttm): 0.407
Qtrly Revenue Growth (yoy): 32.60%
Gross Profit (ttm): 28.25M
EBITDA (ttm): -9.89M
Net Income Avl to Common (ttm): -33.65M
Diluted EPS (ttm): -0.27
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 67.42M
Total Cash Per Share (mrq): 0.517
Total Debt (mrq): 756.00K
Total Debt/Equity (mrq): 0.017
Current Ratio (mrq): 1.476
Book Value Per Share (mrq): 0.332
Cash Flow Statement
Operating Cash Flow (ttm): -10.96M
Levered Free Cash Flow (ttm): 32.74M
TRADING INFORMATION
Stock Price History
Beta: 2.86
52-Week Change3: -28.84%
S&P500 52-Week Change3: 6.76%
52-Week High (13-Jun-05)3: 2.85
52-Week Low (18-Apr-06)3: 1.33
50-Day Moving Average3: 1.81
200-Day Moving Average3: 1.84
Share Statistics
Average Volume (3 month)3: 1,073,060
Average Volume (10 day)3: 1,783,640
Shares Outstanding: 130.30M
Float: 129.22M
% Held by Insiders4: 12.87%
% Held by Institutions4: 67.10%
Shares Short (as of 10-May-06)3: 7.94M
Short Ratio (as of 10-May-06)3: 4.9
Short % of Float (as of 10-May-06)3: 6.10%
Shares Short (prior month)3: 6.79M
Dividends & Splits
Forward Annual Dividend Rate5: N/A
Forward Annual Dividend Yield5: N/A
Trailing Annual Dividend Rate3: N/A
Trailing Annual Dividend Yield3: NaN%
5 Year Average Dividend Yield5: N/A
Payout Ratio5: N/A
Dividend Date3: N/A
Ex-Dividend Date5: N/A
Last Split Factor (new per old)2: N/A
Last Split Date3: N/A
dagoweb
Brigata Falkland
- Registrato
- 20/1/04
- Messaggi
- 5.526
- Punti reazioni
- 266
* La notizia e' vecchia, ma ogni volta che mi ricapita sotto gli occhi mi fa un certo effetto ...
* Quasi quasi ci starebbe un'entrata a questi prezzi (siamo intorno a 1,60) con uno sl a 1,50 ... sono seriamente tentato
Pfizer, Inc (NYSE
FE) recently invested $25 million in Monogram through a 3% Senior Secured Convertible Note, with a conversion price that has been initially set at $2.7048 per share.
* Quasi quasi ci starebbe un'entrata a questi prezzi (siamo intorno a 1,60) con uno sl a 1,50 ... sono seriamente tentato
Pfizer, Inc (NYSE
FE) recently invested $25 million in Monogram through a 3% Senior Secured Convertible Note, with a conversion price that has been initially set at $2.7048 per share.
dagoweb
Brigata Falkland
- Registrato
- 20/1/04
- Messaggi
- 5.526
- Punti reazioni
- 266
http://biz.yahoo.com/prnews/060725/nytu065.html?.v=58
Comunicata la trimestrale.
Con questi dati sono curioso di vedere se regge 1,60 / 1,50.
Per quanto riguarda i 2 $$ rinviati a data da destinarsi (a meno di clamorose novita').
Comunicata la trimestrale.
Con questi dati sono curioso di vedere se regge 1,60 / 1,50.
Per quanto riguarda i 2 $$ rinviati a data da destinarsi (a meno di clamorose novita').
dagoweb
Brigata Falkland
- Registrato
- 20/1/04
- Messaggi
- 5.526
- Punti reazioni
- 266
Aggiornamento multipli :
Market Cap (intraday): 227.24M
Enterprise Value (6-Aug-06)3: 217.30M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-07) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 4.33
Price/Book (mrq): 9.61
Enterprise Value/Revenue (ttm)3: 4.14
Enterprise Value/EBITDA (ttm)3: -25.737
Fiscal Year
Fiscal Year Ends: 31-Dec
Most Recent Quarter (mrq): 30-Jun-06
Profitability
Profit Margin (ttm): -106.79%
Operating Margin (ttm): -32.04%
Management Effectiveness
Return on Assets (ttm): -8.53%
Return on Equity (ttm): -115.74%
Income Statement
Revenue (ttm): 52.47M
Revenue Per Share (ttm): 0.408
Qtrly Revenue Growth (yoy): 7.80%
Gross Profit (ttm): 28.25M
EBITDA (ttm): -8.44M
Net Income Avl to Common (ttm): -56.19M
Diluted EPS (ttm): -0.44
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 35.15M
Total Cash Per Share (mrq): 0.269
Total Debt (mrq): 25.20M
Total Debt/Equity (mrq): 1.066
Current Ratio (mrq): 3.102
Book Value Per Share (mrq): 0.181
Cash Flow Statement
Operating Cash Flow (ttm): N/A
Levered Free Cash Flow (ttm): N/A
Market Cap (intraday): 227.24M
Enterprise Value (6-Aug-06)3: 217.30M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-07) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 4.33
Price/Book (mrq): 9.61
Enterprise Value/Revenue (ttm)3: 4.14
Enterprise Value/EBITDA (ttm)3: -25.737
Fiscal Year
Fiscal Year Ends: 31-Dec
Most Recent Quarter (mrq): 30-Jun-06
Profitability
Profit Margin (ttm): -106.79%
Operating Margin (ttm): -32.04%
Management Effectiveness
Return on Assets (ttm): -8.53%
Return on Equity (ttm): -115.74%
Income Statement
Revenue (ttm): 52.47M
Revenue Per Share (ttm): 0.408
Qtrly Revenue Growth (yoy): 7.80%
Gross Profit (ttm): 28.25M
EBITDA (ttm): -8.44M
Net Income Avl to Common (ttm): -56.19M
Diluted EPS (ttm): -0.44
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 35.15M
Total Cash Per Share (mrq): 0.269
Total Debt (mrq): 25.20M
Total Debt/Equity (mrq): 1.066
Current Ratio (mrq): 3.102
Book Value Per Share (mrq): 0.181
Cash Flow Statement
Operating Cash Flow (ttm): N/A
Levered Free Cash Flow (ttm): N/A
dagoweb
Brigata Falkland
- Registrato
- 20/1/04
- Messaggi
- 5.526
- Punti reazioni
- 266
E' ritornata ad 1,80
per chi avesse creduto al supporto di 1,30 avrebbe fatto un buon affare.
Adesso bisognera' vedere se ritornera' ad oscillare tra 1,80 e 2 oppure mette la marcia indietro.
Continuo ad essere convinto che fara' il vero salto di qualita' solo sopra i 2 $$
,ma per farlo dovra' tirare fuori qualche notizia piu' che positiva altrimenti nisba, anche perche' come multipli e' sicuramente "tirata" :
Market Cap (intraday): 235.18M
Enterprise Value (31-Aug-06)3: 146.85M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-07) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 4.36
Price/Book (mrq): 9.67
Enterprise Value/Revenue (ttm)3: 3.04
Enterprise Value/EBITDA (ttm)3: -14.379
per chi avesse creduto al supporto di 1,30 avrebbe fatto un buon affare.
Adesso bisognera' vedere se ritornera' ad oscillare tra 1,80 e 2 oppure mette la marcia indietro.
Continuo ad essere convinto che fara' il vero salto di qualita' solo sopra i 2 $$
,ma per farlo dovra' tirare fuori qualche notizia piu' che positiva altrimenti nisba, anche perche' come multipli e' sicuramente "tirata" :
Market Cap (intraday): 235.18M
Enterprise Value (31-Aug-06)3: 146.85M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-07) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 4.36
Price/Book (mrq): 9.67
Enterprise Value/Revenue (ttm)3: 3.04
Enterprise Value/EBITDA (ttm)3: -14.379
